Sareum Holdings PLC (LON:SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, has announced that its CEO, Dr Tim Mitchell, will give a company presentation at BIO Digital 2020, which will be delivered on-line from June 8-12, 2020.
It said the presentation will highlight Sareum's two proprietary TYK2/JAK1 kinase inhibitor programmes, SDC-1801 and SDC-1802, targeting autoimmune diseases and cancers, respectively.
Dr Mitchell will also outline the emerging potential of this mechanism to modulate the severe inflammatory responses and respiratory symptoms arising from coronavirus and other viral infections, the group added.
For 2020, the BIO International Convention will transition to a new, virtual event format, BIO Digital. This virtual gathering of the global biotech industry provides access to key partners via BIO One-on-One Partnering, educational resources to help drive participant's businesses, and the insights needed to continue critical research and development.
The presentation will be made through the BIO Digital website and will be available on-demand to registered participants during the conference: www.bio.org/events/bio-digital/sessions/685707
A copy of the presentation will also be made available on Sareum's website: www.sareum.co.uk.
The company also noted that its website has been updated to include information on the potential of its SDC-1801 TYK2/JAK1 inhibitor in the fight against coronavirus (COVID-19), which available at: www.sareum.com/discovery/tyk2jak1-covid19/